Abstract
We conducted a multicentered prospective double-blind placebo controlled trial of rifampin (R) chemoprophylaxis (10 mg/kg bid x2 days). 396 contacts of 79 patients with HIB disease participated. HIB carriage eradication rates were 63.6% and 23.9% for R and placebo, respectively, when all carriers were analyzed. However, in carriers < age 5, R was not significantly better than placebo for HIB eradication. We have recently completed a second chemoprophylaxis trial comparing eradication rates of R (10 mg/kg bid x2 days) and an investigational antibiotic trimethoprim/rifampin (TR), (2.6 mg/kg T and 10 mg/kg R bid x2 days). 139 index patients were identified with invasive HIB disease. 142 of 618 contacts were carriers of HIB and received either R or TR. Carriage eradication rates were 76.8% and 76.3% for R and TR respectively. In children <5, eradication rates were 70% and 68.4% for R and TR. Carriers who remained positive after completing 2 days of TR were offered a 4 day course of R (20 mg/kg/day qd x4 days). 4 of 13 carriers who participated in the cross-over trial remained positive after 4 days of R. We conclude that neither R nor TR in these doses and schedules reliably eradicates HIB carriage in culture positive contacts. In addition, a 4 day course of R was not uniformly successful in those individuals who failed TR therapy.
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Glode, M., Daum, R., Goldmann, D. et al. 1013 CHEMOPROPHYLAXIS FOR CONTACTS OF CHILDREN WITH INVASIVE HAEMOPHILUS INFLUENZAE TYPE B (HIB) DISEASE. Pediatr Res 15 (Suppl 4), 611 (1981). https://doi.org/10.1203/00006450-198104001-01039
Issue Date:
DOI: https://doi.org/10.1203/00006450-198104001-01039